As of November 6, 2026, Nurix Therapeutics, Inc. is a publicly traded company (Nasdaq: NRIX); its largest reported holder is Redmile Group, LLC, with 8.1% on Schedule 13G/A of August 14, 2026, then Vestal Point Capital, LP (7.8%). The largest insider holding is Gwenn Hansen, the chief scientific officer, with 123,452 shares (0.11% of shares outstanding), per Form 4 of November 2, 2026 (Schedule 13G/A, August 14, 2026).
Is this your company?
About to sign with, pay or invest in Nurix Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Nurix Therapeutics, Inc. a real, registered company?
- Nurix Therapeutics, Inc. files with the SEC under CIK 1549595 (its SEC filings).
- Its shares are listed under the ticker NRIX on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Brisbane, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under NURIX THERAPEUTICS INC in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Perceptive Advisors (filed 2026-09-23).
Who are Nurix Therapeutics, Inc.'s owners and officers?
Nurix Therapeutics, Inc.: incorporated in Delaware; business address in Brisbane, California; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-11-05).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-11-05 | Fmr LLC | 4.2% |
| Schedule 13G, 2026-09-23 | Perceptive Advisors LLC | 5.3% |
| Schedule 13G/A, 2026-08-14 | Vestal Point Capital, LP | 7.8% |
| Schedule 13G, 2026-08-14 | T. Rowe Price Associates, Inc. | 5.3% |
| Schedule 13G/A, 2026-08-14 | Deep Track Capital, LP | 7.45% |
| Schedule 13G/A, 2026-08-14 | Redmile Group, LLC | 8.1% |
| Schedule 13G, 2026-08-14 | Rubric Capital Management LP | 6.96% |
| Schedule 13G, 2026-07-31 | Vanguard Capital Management | 5.03% |
| Schedule 13G, 2026-05-15 | Vestal Point Capital, LP | 6.3% |
| Schedule 13G/A, 2026-05-15 | Deep Track Capital, LP | 6.17% |
| Schedule 13G, 2026-05-06 | Fmr LLC | 5.4% |
| Schedule 13G/A, 2026-04-24 | Redmile Group, LLC | 9.9% |
Questions about who owns Nurix Therapeutics, Inc.
Who owns Nurix Therapeutics, Inc.?
On this page, 7 holders' latest ownership filings report 5% or more of Nurix Therapeutics, Inc.: Redmile Group, LLC (8.1%, Schedule 13G/A, filed 2026-08-14), Vestal Point Capital, LP (7.8%, Schedule 13G/A, filed 2026-08-14), Deep Track Capital, LP (7.45%, Schedule 13G/A, filed 2026-08-14), Rubric Capital Management LP (6.96%, Schedule 13G, filed 2026-08-14) and Perceptive Advisors LLC (5.3%, Schedule 13G, filed 2026-09-23); 2 more are listed above.
Who are the largest shareholders of Nurix Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Nurix Therapeutics, Inc. on this page are Redmile Group, LLC (8.1%), Vestal Point Capital, LP (7.8%) and Deep Track Capital, LP (7.45%).
When did Redmile Group, LLC buy into Nurix Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Redmile Group, LLC on this page is the Schedule 13G/A, filed 2026-04-24, reporting 9.9%; its latest, Schedule 13G/A filed 2026-08-14, reports 8.1%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Nurix Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Nurix Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Nurix Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Nurix Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief scientific officer: 123,452 shares (0.11% of shares outstanding) (Form 4, 2026-11-02).
- , the chief financial officer: 42,745 shares (0.04% of shares outstanding) (Form 4, 2026-11-04).
- , a director: 10,750 shares (0.01% of shares outstanding) (Form 4, 2026-10-14).
- , the chief legal officer: 4,406 shares (0.00% of shares outstanding) (Form 4, 2026-11-04).
Shares outstanding: 109,249,814 as of 2026-09-30, from the company's latest SEC cover page.
How much has Nurix Therapeutics, Inc. raised?
No fundraising or offering filing from Nurix Therapeutics, Inc. is on file with us.
Keep reading
More on Nurix Therapeutics, Inc. and the records around it.
Nurix Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
Companies that share a holder
- Redmile Group, LLC also filed stake reports on 18 other companies: FATE THERAPEUTICS INC (Nov 2026), Electra Therapeutics, Inc. (Sep 2026), Neurogene Inc. (Aug 2026)
- Baker Bros. Advisors LP also filed stake reports on 25 other companies: Madrigal Pharmaceuticals, Inc. (Nov 2026), Kodiak Sciences Inc. (Sep 2026), BeOne Medicines Ltd. (Sep 2026)
- Vestal Point Capital, LP also filed stake reports on 27 other companies: Alto Neuroscience, Inc. (Aug 2026), iBio, Inc. (Aug 2026), Immunocore Holdings plc (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/nurix-therapeutics